'Reasonable pricing' spawns a conflict

WASHINGTON - The National Institutes of Health and Myriad Genetics Inc. said that a report last week in The Wall Street Journal exaggerated the intensity of a disagreement between the company and NIH over patent rights to the BRCA1 gene, identifed as a cause of inherited breast cancer.

The newspaper's article said the NIH was unhappy that its scientists who engaged in the search for the gene were not included as co-inventors in the patent filed by the University of Utah...